In this article, we will take a look at Billionaire Stan Druckenmiller’s 10 Stock Picks with Huge Upside Potential.
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital. Having amassed his fortune via a prosperous thirty-year career managing hedge funds, today he oversees investments through his family firm. His stint as head trader at the Quantum Fund, where he collaborated with renowned financier George Soros, helped him define his unique approach to investing.
Renowned for using what he calls a disciplined and well-timed trading rhythm, Druckenmiller uses a top-down approach that combines long and short bets in order to profit from market trends. The Financial Times reports that in his years of managing his hedge fund and the family office, the seasoned investor has never had a down year.
With two of his protégés now well-established in Donald Trump’s inner circle, the 71-year-old billionaire’s influence is also growing beyond the realm of high finance. Druckenmiller’s opinions on economic policy have instantly gained greater clout thanks to Kevin Warsh, a strong candidate to become the next chair of the Federal Reserve, and Scott Bessent, the US president’s Treasury secretary.
Despite this, the billionaire has made it clear that he dislikes President Donald Trump’s sweeping “reciprocal tariffs” and the subsequent market selloff, stating that he doesn’t think taxes on imports should be more than 10%.
Stanley Druckenmiller of Duquesne Capital
Our Methodology
For this article, we examined Duquesne Capital’s Q1 2025 13F filings to list down Stanley Druckenmiller’s stock picks with the highest upside potential. We ranked the companies in ascending order of their upside potential. These equities are also popular among elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Duquesne Capital’s Stake Value: $15.1 million
Analyst Upside as of June 15: 44.20%
Number of Hedge Fund Holders: 59
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. With a price target of $63, Piper Sandler analysts reaffirmed their Overweight rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on June 6. The analysts drew attention to the upcoming Phase 3 topline readout of the CALIBRATE study for BridgeBio Pharma’s calcilytic medication encaleret. The study’s findings are expected to be made public in the second half of 2025.
According to the analysts, the CALIBRATE study, which includes 67 individuals with autosomal dominant hypocalcemia type 1 (ADH1), is expected to have a favorable outcome given the positive efficacy findings from the Phase 2b study of encaleret in patients with ADH1. With a 40% discount, they calculated that risk-adjusted peak sales for ADH1 in the American and EU markets would amount to $389 million. This figure is equivalent to about 9% of BridgeBio Pharma’s overall product revenue.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that was founded to discover, develop, evaluate, and market cutting-edge medication to cure genetic illnesses.